LENZ Therapeutics
LENZ
About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Employees: 42
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3,662% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $305K
253% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 15
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
34% more capital invested
Capital invested by funds: $542M [Q1] → $725M (+$183M) [Q2]
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
11.34% more ownership
Funds ownership: 76.52% [Q1] → 87.85% (+11.34%) [Q2]
8% more funds holding
Funds holding: 105 [Q1] → 113 (+8) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Citigroup
Yigal Nochomovitz
|
$52
|
Buy
Maintained
|
1 Aug 2025 |
|
HC Wainwright & Co.
Matthew Caufield
|
$56
|
Buy
Maintained
|
1 Aug 2025 |
|
Raymond James
Gary Nachman
|
$40
|
Outperform
Maintained
|
31 Jul 2025 |
Financial journalist opinion
Based on 3 articles about LENZ published over the past 30 days
